Supplements

Stapokibart improves sleep quality in patients with chronic rhinosinusitis with nasal polyps

In a post hoc analysis of the phase 3 CROWNS-2 study, stapokibart significantly improved SNOT-22 Sleep domain scores compared with placebo during the 24-week double-blind period. These improvements were maintained and further progressed during the open-label extension and safety follow-up periods, indicating sustained benefit for sleep quality.

Last updated: Jul 7, 2026โ€ข1 RCTsโ€ข๐Ÿ“– Read as article โ†’

Evidence Score

Evidence Score42/100
Human RCTโ˜…โ˜…โ˜†โ˜†โ˜†
Meta-analysisโ˜†โ˜†โ˜†โ˜†โ˜†
Mechanismโ˜…โ˜…โ˜…โ˜…โ˜…
Safetyโ˜…โ˜…โ˜…โ˜…โ˜†
Confidencelow

Study Evidence

Study 1. [Quality of life improvement with stapokibart in chronic rhinosinusitis with nasal polyps: a post hoc analysis of phase 3 CROWNS-2 study].

observational

Yan B, Jin Z, Zhang L, Wang C ยท Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery (2026)

Participants: N/A
Duration: 24 weeks double-blind, plus 28 weeks open-label, plus 8-week follow-up
Intervention: Stapokibart (anti-IL-4Rฮฑ monoclonal antibody) 300 mg every 2 weeks for 24 weeks, followed by open-label extension for 28 weeks
Outcome: 22-item sinonasal outcome test (SNOT-22) domain scores: Nasal, Ear/facial, Sleep, and Emotion
Effect Size: N/A (specific effect sizes not reported in abstract)
Population: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the phase 3 CROWNS-2 study

Result:

PubMed: 42402685DOI: 10.13201/j.issn.2096-7993.2026.07.010

Mechanism Graph

Stapokibart binds to IL-4 receptor ฮฑ subunit
โ†“
Blocks IL-4 and IL-13 signaling pathways
โ†“
Reduces type 2 inflammation in nasal and sinus mucosa
โ†“
Improves sinonasal symptoms including sleep disturbance

Limitations

  • โš Post hoc analysis, not pre-specified primary endpoint
  • โš No specific sleep quality metrics beyond SNOT-22 domain score
  • โš Limited generalizability due to single study design

Frequently Asked Questions

What is stapokibart?โ–ผ

Stapokibart is an anti-interleukin-4 receptor ฮฑ monoclonal antibody that blocks IL-4 and IL-13 signaling pathways, used for treating chronic rhinosinusitis with nasal polyps.

How was sleep quality measured in this study?โ–ผ

Sleep quality was measured using the Sleep domain of the 22-item Sinonasal Outcome Test (SNOT-22), a validated patient-reported outcome instrument.

How long did the sleep improvements last?โ–ผ

Sleep improvements were maintained and further progressed during the 28-week open-label extension and subsequent 8-week safety follow-up period.

What is the CROWNS-2 study?โ–ผ

CROWNS-2 is a phase 3 randomized controlled trial evaluating stapokibart versus placebo in patients with chronic rhinosinusitis with nasal polyps, with a 24-week double-blind period followed by open-label extension.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Yan B, Jin Z, Zhang L, Wang C. "[Quality of life improvement with stapokibart in chronic rhinosinusitis with nasal polyps: a post hoc analysis of phase 3 CROWNS-2 study].." Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery, 2026. PMID: 42402685 DOI: 10.13201/j.issn.2096-7993.2026.07.010
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.